ChiCTR2100045051 版本V1.0 版本创建时间2021/11/02 19:12:37 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100045051 

最近更新日期:

Date of Last Refreshed on:

2021-04-04 05:58:08 

注册时间:

Date of Registration:

2021-04-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

冷冻溶脂治疗后迟发性疼痛的前瞻性研究

Public title:

Prospective Study on Delayed Onset Pain associated with Cryolipolysis Treatment

注册题目简写:

English Acronym:

研究课题的正式科学名称:

冷冻溶脂治疗后迟发性疼痛的前瞻性研究

Scientific title:

Prospective Study on Delayed Onset Pain associated with Cryolipolysis Treatment

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

钟华 

研究负责人:

钟华 

Applicant:

ZHONG HUA 

Study leader:

ZHONG HUA 

申请注册联系人电话:

Applicant telephone:

023-63213666

研究负责人电话:

Study leader's
telephone:

023-63213666

申请注册联系人传真 :

Applicant Fax:

023-63213666

研究负责人传真:

Study leader's fax:

023-63213666

申请注册联系人电子邮件:

Applicant E-mail:

cherryzhong@distinctclinic.com

研究负责人电子邮件:

Study leader's E-mail:

cherryzhong@distinctclinic.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝北区红锦大道92号恒大中心一号楼14层卓正医疗

研究负责人通讯地址:

重庆市渝北区红锦大道92号恒大中心一号楼14层卓正医疗

Applicant address:

Distinct Clinic, 14th Floor, Building 1, Evergrande Zhongyu Plaza, No.92 Hongjin Ave, Yubei District, Chongqing

Study leader's address:

Distinct Clinic, 14th Floor, Building 1, Evergrande Zhongyu Plaza, No.92 Hongjin Ave, Yubei District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

卓正医疗

Applicant's institution:

Distinct Clinic

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

OAS-EAC001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

卓正医疗医学伦理委员会

Name of the ethic committee:

Distinct Health Care Medical Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2021-03-16 00:00:00

伦理委员会联系人:

杨伟洪

Contact Name of the ethic committee:

YANG Weihong

伦理委员会联系地址:

深圳市南山区南海大道与工业四路交汇处万融大厦A座5层D室

Contact Address of the ethic committee:

Room D, 5F, Building A, Wanrong Building, Intersection of Nanhai Avenue and Gongye Fourth Road, Nanshan District, Shenzhen

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

卓正医疗

Primary sponsor:

Distinct Clinic

研究实施负责(组长)单位地址:

重庆市渝北区红锦大道92号恒大中心一号楼14层卓正医疗

Primary sponsor's address:

Distinct Clinic, 14th Floor, Building 1, Evergrande Zhongyu Plaza, No.92 Hongjin Ave, Yubei District, Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

卓正医疗

具体地址:

金田路3037号金中环国际商务大厦40楼

Institution
hospital:

Distinct Clinic

Address:

92 Hongjin Avenue, Yubei District.

经费或物资来源:

自筹资金

Source(s) of funding:

Self-raised funds

研究疾病:

局部肥胖  

Target disease:

Local obesity

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

主要目的:了解冷冻溶脂治疗后迟发性疼痛的发生率 次要目的:观察疼痛规律、相关因素 探索性目的:常见干预方式对疼痛的影响  

Objectives of Study:

Main objective: To investigate the incidence of late onset pain after cryolipolysis therapy Secondary purpose: To observe the regularity and related factors of pain Exploratory purpose: The effects of common interventions on pain

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

预计期限内在卓正医疗接受冷冻溶脂治疗的所有18-60岁病例

Inclusion criteria

All patients aged between 18 and 60 years who received cryolipolysis treatment at Distinct Clinic in the expected period.

排除标准:

1)治疗区域存在感染、伤口、活动性出血,湿疹,皮炎,或皮疹
2) 冷球蛋白血症,冷凝集素综合征,阵发性冷性血红蛋白尿
3) 出血性疾病或合并使用血液稀释剂
4) 心理、精神障碍,心、肺、肾、肝功能不全
5) 治疗部位或相邻部位有疝气,重度腹直肌分离
6) 妊娠或哺乳期女性
7) 已知对低温敏感,例如:寒冷性荨麻疹或雷诺氏病
8) 神经性障碍,例如:带状疱疹后神经痛或糖尿病性神经病
9) 治疗部位出现外周循环受损
10) 需治疗部位在一年内手术或其他疤痕
11) 其他影响治疗的情况

Exclusion criteria:

1)Infection, wound, active bleeding, eczema, dermatitis, or any other rashes in the site to be treated
2) cryoglobulinemia, cold agglutinin syndrome, paroxysmal cold hemoglobinuria
3) Hemorrhagic disease or combined use of blood thinners
4) Psychological and mental disorders, heart, lung, kidney and liver dysfunction
5) Hernia at the treatment site or adjacent site, severe rectus abdominis separation
6) Pregnant or lactating women
7) Sensitivity to cold, such as frigid urticaria or Raynaud's disease
8) Neurological disorders, such as postherpetic neuralgia or diabetic neuropathy
9) Peripheral circulation is impaired at the site to be treated
10) The site to be treated had been operated on within a year or has other scars
11) Other conditions that may affect treatment

研究实施时间:

Study execute time:

From 2021-04-01 00:00:00 To 2022-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-04-01 00:00:00 To 2022-01-31 00:00:00

干预措施:

Interventions:

组别:

连续入组

样本量:

167

Group:

cases series

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

深圳 

市(区县):

 

Country:

China

Province:

Shenzhen

City:

单位(医院):

卓正医疗 

单位级别:

诊所 

Institution
hospital:

Distinct Clinic

Level of the institution:

Clinic

国家:

中国

省(直辖市):

广州 

市(区县):

 

Country:

China

Province:

Guangzhou

City:

单位(医院):

卓正医疗 

单位级别:

诊所 

Institution
hospital:

Distinct Clinic

Level of the institution:

Clinic

国家:

中国

省(直辖市):

长沙 

市(区县):

 

Country:

China

Province:

Changsha

City:

单位(医院):

卓正医疗 

单位级别:

诊所 

Institution
hospital:

Distinct Clinic

Level of the institution:

Clinic

国家:

中国

省(直辖市):

成都 

市(区县):

 

Country:

China

Province:

Chengdu

City:

单位(医院):

卓正医疗 

单位级别:

诊所 

Institution
hospital:

Distinct Clinic

Level of the institution:

Clinic

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

卓正医疗 

单位级别:

诊所 

Institution
hospital:

Distinct Clinic

Level of the institution:

Clinic

国家:

中国

省(直辖市):

杭州 

市(区县):

 

Country:

China

Province:

Hangzhou

City:

单位(医院):

卓正医疗 

单位级别:

诊所 

Institution
hospital:

Distinct Clinic

Level of the institution:

Clinic

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

卓正医疗 

单位级别:

诊所 

Institution
hospital:

Distinct Clinic

Level of the institution:

Clinic

测量指标:

Outcomes:

指标中文名:

疼痛开始时间

指标类型:

主要指标

Outcome:

Begining time of pain

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

VAS疼痛评分

指标类型:

主要指标

Outcome:

VAS pain grade

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛缓解时间

指标类型:

主要指标

Outcome:

Pain relief time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛持续时间

指标类型:

主要指标

Outcome:

Duration of pain

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛性质

指标类型:

主要指标

Outcome:

Pain Properties

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

劳动强度

指标类型:

次要指标

Outcome:

The intensity of labor

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

年龄

指标类型:

次要指标

Outcome:

Age

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

性别

指标类型:

次要指标

Outcome:

Gender

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

身高

指标类型:

次要指标

Outcome:

Height

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重

指标类型:

次要指标

Outcome:

Weight

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

运动习惯

指标类型:

次要指标

Outcome:

Exercise habits

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

吸烟

指标类型:

次要指标

Outcome:

smoking

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

饮酒

指标类型:

次要指标

Outcome:

drinking

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗体位

指标类型:

次要指标

Outcome:

Treatment of position

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗部位

指标类型:

次要指标

Outcome:

treatment position

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

点位数

指标类型:

次要指标

Outcome:

Therapeutic cycles

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗区域重叠百分比

指标类型:

次要指标

Outcome:

Percentage of treatment area overlap

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

两次治疗间隔

指标类型:

次要指标

Outcome:

Time interval between two treatments

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

干预措施

指标类型:

附加指标

Outcome:

intervening measures

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

non-random

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床研究公共管理平台

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Research Manager, ResMan

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

利用病例记录表和随访表收集和整理数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data were collected and collated from CRF and follow-up form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-04-04 05:58:08